CBD improves symptoms of arthritis in dogs
Study shows CBD relieves arthritis pain In dogs. Research, which could pave the way for a human application.
A team led by researchers at Baylor College of Medicine in collaboration with Medterra CBD conducted the first scientific studies to assess the potential therapeutic effects of cannabidiol (CBD) for arthritis pain in dogs, and the results could pave the way for l study of its effects in humans.
Researchers initially focused on these animals because their condition closely mimics the characteristics of human arthritis, the leading cause of pain and disability in the United States for which there is no effective treatment. Published in the journal PAIN, the study first showed in both laboratory tests and mouse models that CBD, a non-addictive product derived from hemp (cannabis), can dramatically reduce the production of inflammatory molecules and immune cells associated with arthritis.
Subsequently, the study showed that in dogs diagnosed with the disease, treatment with CBD significantly improved quality of life, as shown by owner and vet reviews. This work supports the future scientific evaluation of CBD for human arthritis.
“CBD is rapidly gaining popularity due to its anecdotal health benefits for a variety of conditions, from anxiety reduction to aid with movement disorders,” said corresponding author Dr Matthew Halpert, research professor in the Department of Pathology and Immunology at Baylor. “In 2019, Medterra CBD approached Baylor to conduct independent scientific studies to determine the biological capabilities of several of its products.”
In the current study, Halpert and colleagues first measured the effect of CBD on immune responses associated with arthritis, both in human and murine cells grown in the lab and in mouse models. Using Medterra tinctures, they found that treatment with CBD resulted in reduced production of inflammatory molecules and immune cells linked to arthritis.
The researchers also determined that the effect was faster and more effective when the CBD was administered encapsulated in liposomes than when it was administered “naked”. Liposomes are tiny, artificially formed spherical sacs that are used to deliver drugs and other substances into tissues at higher absorption rates.
Halpert and his colleagues then evaluated the effect of naked and liposome-encapsulated CBD on the quality of life of dogs with arthritis.
“We studied dogs because experimental evidence shows that spontaneous models of arthritis, especially in domestic canine models, are more suitable for evaluating treatments for human arthritis pain than other animal models. The biological characteristics of arthritis in dogs closely resemble those of the human condition, ”according to Halpert.
Arthritis is a common condition in dogs. According to the American Kennel Club, it affects one in five dogs in the United States.
The 20 dogs belonging to clients enrolled in the study were seen at Sunset Animal Hospital in Houston. Dog owners were randomly given vials of identical unidentified drugs containing CBD, liposomal CBD or a placebo. Neither the owners nor the vet knew what treatment each dog was receiving.
After four weeks of daily treatment, owners and vets reported on the dog’s condition, if they observed any changes in the animal’s pain level, such as changes in running or gait. The dog’s complete blood count and blood indicators of liver and kidney function were also assessed before and after the four weeks of treatment.
“We have found encouraging results,” said Halpert. “Nine out of ten dogs on CBD showed benefits, which lasted for two weeks after stopping treatment. We did not detect any alterations in the blood markers we measured, suggesting that under the conditions of our study, the treatment appears to be safe.”